Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(4 sites)
France
Institut du Cancer de Montpellier, Montpellier Italy
Fondazione IRCCS Istituto Nazionale dei Tumori, Milan IRCCS Ospedale San Raffaele, Milan Azienda Unità Sanitaria Locale - IRCCS di Reggio Emilia, Reggio Emilia